Resource Summary Report

Generated by NIF on Jul 31, 2026

Mouse Anti-Cytokeratin, pan Monoclonal Antibody, Unconjugated, Clone C-11

RRID:AB_306047
Type: Antibody

Proper Citation

Abcam Cat# ab7753, RRID:AB_306047

Antibody Information

URL: http://antibodyregistry.org/AB_306047

Proper Citation: Abcam Cat# ab7753, RRID:AB_306047

Target Antigen: pan Cytokeratin

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Immunocytochemistry; Immunohistochemistry; Immunoprecipitation; Western Blot; Immunocytochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-P, Immunoprecipitation, Western Blot

Antibody Name: Mouse Anti-Cytokeratin, pan Monoclonal Antibody, Unconjugated, Clone C-11

Description: This monoclonal targets pan Cytokeratin

Target Organism: all

Clone ID: Clone C-11

Antibody ID: AB_306047

Vendor: Abcam

Catalog Number: ab7753

Record Creation Time: 20250820T020951+0000

Record Last Update: 20250820T125126+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-Cytokeratin, pan Monoclonal Antibody, Unconjugated, Clone C-11.

No alerts have been found for Mouse Anti-Cytokeratin, pan Monoclonal Antibody, Unconjugated, Clone C-11.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 41 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Zhang Y, et al. (2026) Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. Cancer cell, 44(1), 77.

Chen C, et al. (2026) B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity. Cancer cell.

Zeng L, et al. (2025) Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial. Med (New York, N.Y.), 6(6), 100574.

Chang J, et al. (2025) Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis. Cancer cell, 43(3), 380.

Zhang Y, et al. (2025) Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance. Cell, 188(24), 6754.

Li G, et al. (2025) Microenvironmental ?-TrCP negates amino acid transport to trigger CD8+ T cell exhaustion in human non-small cell lung cancer. Cell reports, 44(1), 115128.

Nguyen DT, et al. (2025) Protein kinase C? dictates tumor trajectory, cell plasticity, and immune surveillance in lung adenocarcinoma. Cell reports, 44(12), 116606.

Lee MR, et al. (2025) Organoid morphology-guided classification for oral cancer reveals prognosis. Cell reports. Medicine, 6(5), 102129.

Tang R, et al. (2025) Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism. Gastroenterology, 169(4), 615.

Xu M, et al. (2025) Effects of anlotinib combined with camrelizumab and chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma on tumor immune microenvironment. Journal of gastrointestinal oncology, 16(4), 1366.

Song L, et al. (2025) Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC. iScience, 28(9), 113211.

Dai D, et al. (2024) Chemoradiotherapy-induced ACKR2+ tumor cells drive CD8+ T cell senescence and cervical cancer recurrence. Cell reports. Medicine, 5(5), 101550.

Zhao J, et al. (2024) Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer. Med (New York, N.Y.), 5(8), 981.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway. Cell genomics, 4(10), 100659.

Gong C, et al. (2024) Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study. Cell reports. Medicine, 5(11), 101807.

Miao N, et al. (2024) Tumor cell-intrinsic Piezo2 drives radioresistance by impairing CD8+ T cell stemness maintenance. The Journal of experimental medicine, 221(10).

Zheng C, et al. (2024) IFN?-induced BST2+ tumor-associated macrophages facilitate immunosuppression and tumor growth in pancreatic cancer by ERK-CXCL7 signaling. Cell reports, 43(4), 114088.

Ning J, et al. (2024) Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation. Cell reports. Medicine, 5(5), 101505.

Luo Y, et al. (2024) Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell, 187(18), 4905.

Yonemura A, et al. (2024) Mesothelial cells with mesenchymal features enhance peritoneal dissemination by forming a protumorigenic microenvironment. Cell reports, 43(1), 113613.